Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat vs Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia
NCT06456346Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of bomedemstat in essential thrombocythemia (ET) (2 arms), sponsored by Merck & Co. Primary endpoint: Durable Clinicohematologic Response Rate at 52 weeks. Started Jul 2024; status: active, not recruiting.
02
Drugs
bomedemstat
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT06456346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06456346.